Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646375 | 0.91 | GAA (0.52) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL12646269 | 0.90 | GAA (0.51) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL10222586 | 0.90 | OPRM1 (0.55) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL10033224 | 0.85 | GAA (0.54) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL12646331 | 0.84 | GAA (0.51) | GAAOPRM1OPRD1OPRK1MAPT | |
| SCHEMBL12588898 | 0.81 | OPRM1 (0.53) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL10391150 | 0.80 | GAA (0.52) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL12588946 | 0.80 | OPRM1 (0.42) | GAAOPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL12588922 | 0.79 | OPRM1 (0.58) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL28925147 | 0.79 | GAA (0.70) | GAAOPRM1OPRD1OPRK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148528-B2 | Processes and compounds for the preparation of normorphinans | MALLINCKRODT LLC (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090299069-A1 | Processes and Compounds for the Preparation of Normorphinans | MALLINCKRODT INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299069-A1 | Processes and Compounds for the Preparation of Normorphinans | CRH, NPSR1, AVPR1B | GAA 1845/4885OPRM1 17/4885OPRD1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.